Amgen Inc. (NASDAQ:AMGN) Shares Acquired by abrdn plc

abrdn plc increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 150.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,043,609 shares of the medical research company’s stock after acquiring an additional 626,810 shares during the quarter. Amgen comprises approximately 0.7% of abrdn plc’s investment portfolio, making the stock its 24th largest holding. abrdn plc’s holdings in Amgen were worth $300,580,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Fuller & Thaler Asset Management Inc. raised its position in Amgen by 1.7% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after purchasing an additional 193 shares during the last quarter. Diversified Trust Co grew its stake in shares of Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares during the last quarter. Nicolet Advisory Services LLC increased its holdings in shares of Amgen by 4.4% in the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares during the period. Platform Technology Partners raised its stake in shares of Amgen by 7.4% during the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock worth $1,567,000 after purchasing an additional 402 shares during the last quarter. Finally, Traynor Capital Management Inc. lifted its holdings in shares of Amgen by 9.5% during the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after purchasing an additional 1,650 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

AMGN traded up $6.18 during trading on Friday, reaching $268.93. The stock had a trading volume of 3,380,330 shares, compared to its average volume of 2,077,465. The stock has a 50 day moving average of $276.90 and a two-hundred day moving average of $281.26. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The firm has a market capitalization of $144.25 billion, a price-to-earnings ratio of 21.53, a price-to-earnings-growth ratio of 2.44 and a beta of 0.58. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the previous year, the business earned $4.09 EPS. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, equities analysts anticipate that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent analyst reports. Morgan Stanley reduced their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Truist Financial reissued a “buy” rating and set a $320.00 price target on shares of Amgen in a research note on Friday, April 12th. Oppenheimer restated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Finally, UBS Group reduced their price target on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a report on Wednesday. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.